Starpharma Holdings Limited

DB:PQ6A Stock Report

Market Cap: €28.1m

Starpharma Holdings Past Earnings Performance

Past criteria checks 0/6

Starpharma Holdings has been growing earnings at an average annual rate of 6.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 12.6% per year.

Key information

6.5%

Earnings growth rate

8.8%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate12.6%
Return on equity-29.0%
Net Margin-83.7%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Starpharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:PQ6A Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2410-870
31 Mar 2410-870
31 Dec 2311-870
30 Sep 237-1270
30 Jun 234-1680
31 Mar 235-1680
31 Dec 225-1670
30 Sep 225-1670
30 Jun 225-1670
31 Mar 225-1770
31 Dec 214-1870
30 Sep 214-1970
30 Jun 213-2070
31 Mar 213-1970
31 Dec 203-1960
30 Sep 205-1760
30 Jun 207-1560
31 Mar 207-1463
31 Dec 198-1375
30 Sep 195-1478
30 Jun 193-14610
31 Mar 194-13610
31 Dec 184-11610
30 Sep 185-11510
30 Jun 185-10511
31 Mar 185-12512
31 Dec 174-13513
30 Sep 174-14414
30 Jun 174-15415
31 Dec 161-20417
30 Sep 163-20419
30 Jun 165-21421
31 Mar 165-22521
31 Dec 155-20421
30 Sep 153-20419
30 Jun 152-19416
31 Mar 151-18515
31 Dec 141-18514
30 Sep 141-16512
30 Jun 141-15511
31 Mar 142-1249
31 Dec 132-947

Quality Earnings: PQ6A is currently unprofitable.

Growing Profit Margin: PQ6A is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PQ6A is unprofitable, but has reduced losses over the past 5 years at a rate of 6.5% per year.

Accelerating Growth: Unable to compare PQ6A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PQ6A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: PQ6A has a negative Return on Equity (-29.04%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies